The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
Open accessAbstract
Suppression of antitumor immune responses is one of the main mechanisms by which tumor cells escape from destruction by the immune system. Myeloid-derived suppressor cells (MDSCs) represent the main immunosuppressive cells present in the tumor microenvironment (TME) that sustain cancer progression. MDSCs are a heterogeneous group of immature myeloid cells with a potent activity against T-cell. Studies in mice have demonstrated that MDSCs accumulate in several types of cancer where they promote invasion, angiogenesis, and metastasis formation and inhibit antitumor immunity. In addition, different clinical studies have shown that MDSCs levels in the peripheral blood of cancer patients correlates with tumor burden, stage and with poor prognosis in multiple malignancies. Thus, MDSCs are the major obstacle to many cancer immunotherapies and their targeting may be a beneficial strategy for improvement the efficiency of immunotherapeutic interventions. However, the great heterogeneity of these cells makes their identification in human cancer very challenging. Since both the phenotype and mechanisms of action of MDSCs appear to be tumor-dependent, it is important to accurately characterized the precise MDSC subsets that have clinical relevance in each tumor environment to more efficiently target them. In this review we summarize the phenotype and the suppressive mechanisms of MDSCs populations expanded within different tumor contexts. Further, we discuss about their clinical relevance for cancer diagnosis and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.007 · Cited by 2,718 · cited 1×
“Recent studies have shown that symbiotic bacteria like Fusobacterium nucleatum and Helicobacter hepaticus can exacerbate the development of cancer by inducing MDSCs expansion in the inflamed colon of mice (121, 122).”
BackgroundZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · cited 1×
“In particular, encouraging results has been obtained with the anti PD-1 mAbs nivolumab and pembrolizumab, which exhibited an objective tumor response of about 20% in HCC patients who had been previously treated with sorafenib (207, 211).”
ResultDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Garrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404 · cited 1×
“Accumulating data also support a role for the microbiota in CRC carcinogenesis (120).”
BackgroundAdams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Jansson, M. D., & Lund, A. H. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.006 · Cited by 1,099
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J., & Umansky, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 839
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 766
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 737
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand-Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 725
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 647
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., Heimbach, J. K., et al. (2019) · Clinical Liver Disease · doi:10.1002/cld.802 · Cited by 645
Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M. P., Greten, T. F., & Korangy, F. (2009) · Hepatology · doi:10.1002/hep.23054 · Cited by 643
Etiology of Hormone Receptor–Defined Breast Cancer: A Systematic Review of the Literature
Althuis, M. D., Fergenbaum, J. H., Garcia-Closas, M., Brinton, L. A., Madigan, M. P., & Sherman, M. E. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.1558.13.10 · Cited by 628
Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608 · cited 1×
“IL-17 appears one of the main driving chemoattractant forces, especially for GMDSCs, within the TME (128).”
BackgroundYu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 606
Lechner, M. G., Liebertz, D. J., & Epstein, A. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000901 · Cited by 582
Youn, J., & Gabrilovich, D. I. (2010) · European Journal of Immunology · doi:10.1002/eji.201040895 · Cited by 568
Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S., & Gabrilovich, D. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1690 · Cited by 564
Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Metastatic Colorectal Cancer: Current State and Future Directions
Fakih, M. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7633 · Cited by 527
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Ostrand-Rosenberg, S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0855-8 · Cited by 521
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Youn, J.-I., Collazo, M., Shalova, I. N., Biswas, S. K., & Gabrilovich, D. I. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311177 · Cited by 510
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 507
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477 · cited 4×
“The frequency of MMDSCs subsets was positively correlated with liver related laboratory parameters, especially AFP and ALT, which reflects a hepatic insult whereas, was inversely related to the frequency of CD4+, CD8+ T, and CD19+ B cells.”
BackgroundResultInfluentialMyeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 443
Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies
Lakatos, P. L., & Lakatos, L. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3937 · Cited by 442
Mechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells
Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A., & Gabrilovich, D. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2593 · Cited by 423
Perrot, I., Michaud, H.-A., Giraudon-Paoli, M., Augier, S., Docquier, A., Gros, L., Courtois, R., Déjou, C., Jecko, D., Becquart, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.091 · Cited by 423
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412
Chun, E., Lavoie, S., Michaud, M., Gallini, C. A., Kim, J., Soucy, G., Odze, R., Glickman, J. N., & Garrett, W. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.024 · Cited by 402 · cited 5×
“The MMDSCs subset defined as HLA-DR−/lowCD14+, resulted to be predominant in melanoma, breast cancer and hepatocellular carcinoma.”
BackgroundResultInfluentialPlasticity of myeloid-derived suppressor cells in cancer
Tcyganov, E., Mastio, J., Chen, E., & Gabrilovich, D. I. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.009 · Cited by 398
Chemokines: agents for the immunotherapy of cancer?
Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398
Il-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
Interleukin-6 in bone metastasis and cancer progression
Ara, T., & DeClerck, Y. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 379
Purine Release, Metabolism, and Signaling in the Inflammatory Response
Linden, J., Koch-Nolte, F., & Dahl, G. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052406 · Cited by 377
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Transcriptional regulation of myeloid-derived suppressor cells
Condamine, T., Mastio, J., & Gabrilovich, D. I. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0515-204r · Cited by 372
Le, H. K., Graham, L., Cha, E., Morales, J. K., Manjili, M. H., & Bear, H. D. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.03.015 · Cited by 368
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
Lu, T., Ramakrishnan, R., Altiok, S., Youn, J.-I., Cheng, P., Celis, E., Pisarev, V., Sherman, S., Sporn, M. B., & Gabrilovich, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45862 · Cited by 367
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J.-I., Celis, E., Finnberg, N., El-Deiry, W. S., Winograd, R., Vonderheide, R. H., English, N. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74056 · Cited by 365
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Mbongue, J., Nicholas, D., Torrez, T., Kim, N.-S., Firek, A., & Langridge, W. (2015) · Vaccines · doi:10.3390/vaccines3030703 · Cited by 351
Meyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
Solito, S., Falisi, E., Diaz-Montero, C. M., Doni, A., Pinton, L., Rosato, A., Francescato, S., Basso, G., Zanovello, P., Onicescu, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-325753 · Cited by 337
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., Wojno, K., Snyder, L. A., Yan, L., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333
Update in global trends and aetiology of hepatocellular carcinoma
Rawla, P., Sunkara, T., Muralidharan, P., & Raj, J. P. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.78941 · Cited by 332
Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression
Ohl, K., & Tenbrock, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02499 · Cited by 330
Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z., & Colombo, M. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1882 · Cited by 329
Sunahori, K., Yamamura, M., Yamana, J., Takasugi, K., Kawashima, M., Yamamoto, H., Chazin, W. J., Nakatani, Y., Yui, S., & Makino, H. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1939 · Cited by 321
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Iclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., & Gabrilovich, D. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1396-8 · Cited by 317
Liu, C.-Y., Wang, Y.-M., Wang, C.-L., Feng, P.-H., Ko, H.-W., Liu, Y.-H., Wu, Y.-C., Chu, Y., Chung, F.-T., Kuo, C.-H., et al. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0634-0 · Cited by 313
Microbiota, Inflammation and Colorectal Cancer
Lucas, C., Barnich, N., & Nguyen, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061310 · Cited by 313
Tarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 310
Sade-Feldman, M., Kanterman, J., Ish-Shalom, E., Elnekave, M., Horwitz, E., & Baniyash, M. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.007 · Cited by 307
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0037 · Cited by 304
Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320011 · Cited by 299
Veltman, J. D., Lambers, M. E., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G., & Hegmans, J. P. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-464 · Cited by 291
Mechanisms of immune evasion in breast cancer
Bates, J. P., Derakhshandeh, R., Jones, L., & Webb, T. J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4441-3 · Cited by 291
Nagaraj, S., Youn, J.-I., Weber, H., Iclozan, C., Lu, L., Cotter, M. J., Meyer, C., Becerra, C. R., Fishman, M., Antonia, S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3272 · Cited by 286
Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kübler, H., Yancey, D., Dahm, P., & Vieweg, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0165 · Cited by 284
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M., Jiao, X., De La Fuente, M., Pestell, T. G., Ertel, A., Lisanti, M. P., & Pestell, R. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282
Porembka, M. R., Mitchem, J. B., Belt, B. A., Hsieh, C.-S., Lee, H.-M., Herndon, J., Gillanders, W. E., Linehan, D. C., & Goedegebuure, P. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1178-0 · Cited by 277
Zhang, B., Wang, Z., Wu, L., Zhang, M., Li, W., Ding, J., Zhu, J., Wei, H., & Zhao, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057114 · Cited by 269
Weed, D. T., Vella, J. L., Reis, I. M., De la fuente, A. C., Gomez, C., Sargi, Z., Nazarian, R., Califano, J., Borrello, I., & Serafini, P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1711 · Cited by 261
Weide, B., Martens, A., Zelba, H., Stutz, C., Derhovanessian, E., Di Giacomo, A. M., Maio, M., Sucker, A., Schilling, B., Schadendorf, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2508 · Cited by 261
A chemokine receptor antagonist inhibits experimental breast tumor growth.
Robinson, S. C., Scott, K. A., Wilson, J. L., Thompson, R. G., Proudfoot, A. E. I., & Balkwill, F. R. (2003) · PubMed · Cited by 259
Arihara, F., Mizukoshi, E., Kitahara, M., Takata, Y., Arai, K., Yamashita, T., Nakamoto, Y., & Kaneko, S. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1447-1 · Cited by 252
Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells
Bronte, V., Serafini, P., Apolloni, E., & Zanovello, P. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200111000-00001 · Cited by 250
Huber, V., Vallacchi, V., Fleming, V., Hu, X., Cova, A., Dugo, M., Shahaj, E., Sulsenti, R., Vergani, E., Filipazzi, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98060 · Cited by 250
Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248
Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., & Umansky, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202781 · Cited by 246
Reilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245
Stiff, A., Trikha, P., Mundy-Bosse, B., McMichael, E., Mace, T. A., Benner, B., Kendra, K., Campbell, A., Gautam, S., Abood, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0691 · Cited by 244
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
Filipazzi, P., Huber, V., & Rivoltini, L. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1161-9 · Cited by 243
Qin, H., Lerman, B., Sakamaki, I., Wei, G., Cha, S. C., Rao, S. S., Qian, J., Hailemichael, Y., Nurieva, R., Dwyer, K. C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3560 · Cited by 233
Zhou, S.-F., Wang, Y.-Y., Zhe, H., Yang, Y., & He, Z. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s68872 · Cited by 231
Characterization of the role of IL-6 in the progression of prostate cancer
Chung, T. D., Yu, J. J., Spiotto, M. T., Bartkowski, M., & Simons, J. W. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990215)38:3<199::aid-pros4>3.0.co;2-h · Cited by 231
On the origin of myeloid-derived suppressor cells
Millrud, C. R., Bergenfelz, C., & Leandersson, K. (2017) · Oncotarget · doi:10.18632/oncotarget.12278 · Cited by 230
Do STAT3 inhibitors have potential in the future for cancer therapy?
Wong, A. L. A., Hirpara, J. L., Pervaiz, S., Eu, J.-Q., Sethi, G., & Goh, B.-C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1351941 · Cited by 225
New insights into chronic inflammation-induced immunosuppression
Kanterman, J., Sade-Feldman, M., & Baniyash, M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.008 · Cited by 224
Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., & Ullenhag, G. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1037-z · Cited by 219
Christmas, B. J., Rafie, C. I., Hopkins, A. C., Scott, B. A., Ma, H. S., Cruz, K. A., Woolman, S., Armstrong, T. D., Connolly, R. M., Azad, N. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0070 · Cited by 219
Mastelic-Gavillet, B., Navarro Rodrigo, B., Décombaz, L., Wang, H., Ercolano, G., Ahmed, R., Lozano, L. E., Ianaro, A., Derré, L., Valerio, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0719-5 · Cited by 216
Self-citationMyeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
Srivastava, M. K., Zhu, L., Harris-White, M., Kar, U., Huang, M., Johnson, M. F., Lee, J. M., Elashoff, D., Strieter, R., Dubinett, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040677 · Cited by 214
Matzner, Y., Bar-Ner, M., Yahalom, J., Ishai-Michaeli, R., Fuks, Z., & Vlodavsky, I. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112104 · Cited by 212
Chen, Y., Huang, Y., Reiberger, T., Duyverman, A. M., Huang, P., Samuel, R., Hiddingh, L., Roberge, S., Koppel, C., Lauwers, G. Y., et al. (2014) · Hepatology · doi:10.1002/hep.26790 · Cited by 211
Huang, A., Zhang, B., Wang, B., Zhang, F., Fan, K.-X., & Guo, Y.-J. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1450-6 · Cited by 210
Myeloid‐derived suppressor cells in cancer: recent progress and prospects
Khaled, Y. S., Ammori, B. J., & Elkord, E. (2013) · Immunology & Cell Biology · doi:10.1038/icb.2013.29 · Cited by 209
Attard, G., Belldegrun, A. S., & De Bono, J. S. (2005) · BJU International · doi:10.1111/j.1464-410x.2005.05821.x · Cited by 207
Roland, C. L., Lynn, K. D., Toombs, J. E., Dineen, S. P., Udugamasooriya, D. G., & Brekken, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007669 · Cited by 207
Therapeutic targeting of myeloid-derived suppressor cells
Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., & Bronte, V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.014 · Cited by 206
Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
Sumanasuriya, S., & De Bono, J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030635 · Cited by 203
Gp91 phox is the heme binding subunit of the superoxide-generating NADPH oxidase
Yu, L., Quinn, M. T., Cross, A. R., & Dinauer, M. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7993 · Cited by 202
Mandruzzato, S., Brandau, S., Britten, C. M., Bronte, V., Damuzzo, V., Gouttefangeas, C., Maurer, D., Ottensmeier, C., van der Burg, S. H., Welters, M. J. P., et al. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1782-5 · Cited by 202
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Immunotherapy for hepatocellular carcinoma: Current and future
Johnston, M. P., & Khakoo, S. I. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.2977 · Cited by 197
Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice
Mundy-Bosse, B. L., Lesinski, G. B., Jaime-Ramirez, A. C., Benninger, K., Khan, M., Kuppusamy, P., Guenterberg, K., Kondadasula, S. V., Chaudhury, A. R., La Perle, K. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2670 · Cited by 189
OuYang, L.-Y., Wu, X.-J., Ye, S.-B., Zhang, R.-X., Li, Z.-L., Liao, W., Pan, Z.-Z., Zheng, L.-M., Zhang, X.-S., Wang, Z., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0410-7 · Cited by 189
Dominguez, G. A., Condamine, T., Mony, S., Hashimoto, A., Wang, F., Liu, Q., Forero, A., Bendell, J., Witt, R., Hockstein, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1784 · Cited by 187
Kapanadze, T., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.010 · Cited by 185
Idorn, M., Køllgaard, T., Kongsted, P., Sengeløv, L., & thor Straten, P. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1591-2 · Cited by 184
Anassi, E., & Ndefo, U. A. (2011) · PubMed Central · Cited by 184
CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Blattner, C., Fleming, V., Weber, R., Himmelhan, B., Altevogt, P., Gebhardt, C., Schulze, T. J., Razon, H., Hawila, E., Wildbaum, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0348 · Cited by 182
On the armament and appearances of human myeloid-derived suppressor cells
Poschke, I., & Kiessling, R. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.06.003 · Cited by 177
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
Wadosky, K. M., & Koochekpour, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10901 · Cited by 174
Feng, P.-H., Lee, K.-Y., Chang, Y.-L., Chan, Y.-F., Kuo, L.-W., Lin, T.-Y., Chung, F.-T., Kuo, C.-S., Yu, C.-T., Lin, S.-M., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0636oc · Cited by 169
Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer
Yamauchi, Y., Safi, S., Blattner, C., Rathinasamy, A., Umansky, L., Juenger, S., Warth, A., Eichhorn, M., Muley, T., Herth, F. J. F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201708-1707oc · Cited by 168
Bergenfelz, C., Larsson, A.-M., von Stedingk, K., Gruvberger-Saal, S. K., Aaltonen, K. E., Jansson, S., Jernström, H., Janols, H., Wullt, M., Bredberg, A. C. A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127028 · Cited by 167
Kanterman, J., Sade-Feldman, M., Biton, M., Ish-Shalom, E., Lasry, A., Goldshtein, A., Hubert, A., & Baniyash, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0657 · Cited by 166
Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J., & Kusmartsev, S. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1209821 · Cited by 160
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 157
Improving cancer immunotherapy by targeting tumor-induced immune suppression
Stewart, T. J., & Smyth, M. J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9280-5 · Cited by 156
Holmgaard, R., Zamarin, D., Lesokhin, A. M., Merghoub, T., & Wolchok, J. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.024 · Cited by 154
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
Schiller, J. H. (2001) · Oncology · doi:10.1159/000055386 · Cited by 153
Mao, Y., Eißler, N., Blanc, K. L., Johnsen, J. I., Kogner, P., & Kiessling, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1912 · Cited by 151
Lathers, D. M. R., Clark, J. I., Achille, N. J., & Young, M. R. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0459-7 · Cited by 149
Analysis of Cyclooxygenase 2 (COX-2) Expression During Malignant Melanoma Progression
Goulet, A.-C., Einsphar, J., Alberts, D. S., Beas, A. O., Burk, C., Bhattacharyya, A. K., Bangert, J. L., Harmon, J. M., Fujiwara, H., Koki, A. T., et al. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.6.627 · Cited by 145
Lee, C., Kwak, Y., Yang, T., Han, J. H., Park, S., Ye, M. B., Lee, W., Sim, K.-Y., Kang, J., Kim, Y., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.062 · Cited by 145
Jordan, K. R., Amaria, R. N., Ramirez, O., Callihan, E., Gao, D., Borakove, M., Manthey, E., Borges, V. F., & McCarter, M. D. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1475-x · Cited by 144
Danilin, S., Merkel, A. R., Johnson, J., Johnson, R. W., Edwards, J., & Sterling, J. A. R. (2012) · OncoImmunology · doi:10.4161/onci.21990 · Cited by 143
Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas
Fujimura, T., Ring, S., Umansky, V., Mahnke, K., & Enk, A. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.416 · Cited by 139
Sun, H.-L., Xin Min, Z. H. O. U., Xue, Y., Wang, K., Shen, Y., Mao, J., Guo, H., & Miao, Z. (2012) · Europe PMC (PubMed Central) · doi:10.3748/wjg.v18.i25.3303 · Cited by 138
Wang, P.-F., Song, S., Wang, T., Ji, W., Li, S., Liu, N., & Yan, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1494113 · Cited by 134
Varney, M. L., Johansson, S. L., & Singh, R. K. (2005) · American Journal of Clinical Pathology · doi:10.1309/vpl5r3jr7f1d6v03 · Cited by 133
Ferretti, G., Fabi, A., Carlini, P., Papaldo, P., Fei, P. C., Cosimo, S. D., Salesi, N., Giannarelli, D., Alimonti, A., Cocco, B. D., et al. (2005) · Oncology · doi:10.1159/000087286 · Cited by 132
Cao, M., Xu, Y., Youn, J., Cabrera, R., Zhang, X., Gabrilovich, D. I., Nelson, D. R., & Liu, C. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2010.205 · Cited by 129
Gonda, K., Shibata, M., Ohtake, T., Matsumoto, Y., Tachibana, K., Abe, N., Ohto, H., Sakurai, K., & Takenoshita, S. (2017) · Oncology Letters · doi:10.3892/ol.2017.6305 · Cited by 129
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Messmer, M. N., Netherby, C. S., Banik, D., & Abrams, S. I. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1639-3 · Cited by 127
CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion
Singh, S., Nannuru, K. C., Sadanandam, A., Varney, M. L., & Singh, R. K. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605055 · Cited by 126
The multifaceted nature of retinoid transport and metabolism
(2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2014.05.04 · Cited by 125
Fujimura, T., Kambayashi, Y., & Aiba, S. (2012) · OncoImmunology · doi:10.4161/onci.21176 · Cited by 122
Nan, J., Xing, Y., Hu, B., Tang, J., Dong, H., He, Y., Ruan, D., Ye, Q., Cai, J., Ma, X., et al. (2017) · Immunology · doi:10.1111/imm.12876 · Cited by 121
MicroRNAs in melanoma development and resistance to target therapy
Fattore, L., Costantini, S., Malpicci, D., Ruggiero, C. F., Ascierto, P. A., Croce, C. M., Mancini, R., & Ciliberto, G. (2017) · Oncotarget · doi:10.18632/oncotarget.14763 · Cited by 120
Sternberg, C. N., Armstrong, A. J., Пили, Р., Ng, S. S. W., Huddart, R. A., Agarwal, N., Khvorostenko, D., Lyulko, O. O., Brize, A., Vogelzang, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9697 · Cited by 114
Sevko, A., & Umansky, V. (2013) · Journal of Cancer · doi:10.7150/jca.5047 · Cited by 113
RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity
Probst, B., Isaac, T., Lyndsey, M., Bumeister, R., Dulubova, I., Wigley, W. C., & Ferguson, D. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122942 · Cited by 110
Kim, H. R., Park, S.-M., Seo, S., Jung, I., Yoon, H. I., Gabrilovich, D. I., Cho, B. C., Seong, S., Ha, S., & Youn, J. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201808-1502le · Cited by 108
Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells
Donkor, M. K., Lahue, E. E., Hoke, T. A., Shafer, L. R., Çoşkun, U., Solheim, J. C., Gülen, D., Bishay, J., & Talmadge, J. E. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.03.021 · Cited by 106
Hoeppner, L. H., Wang, Y., Sharma, A. K., Javeed, N., Keulen, V. P. V., Wang, E., Yang, P., Roden, A. C., Peikert, T., Molina, J. R., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.008 · Cited by 105
Chen, H.-M., Ma, G., Gildener‐Leapman, N., Eisenstein, S. G., Coakley, B. A., Ozao, J. J., Mandeli, J., Divino, C. M., Schwartz, M., Sung, M. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2742 · Cited by 105
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Botti, G., Fratangelo, F., Cerrone, M., Liguori, G., Cantile, M., Anniciello, A. M., Scala, S., D’Alterio, C., Trimarco, C., Ianaro, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1150-7 · Cited by 104
Self-citationHost miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell–Dependent Mechanism
Chen, S., Wang, L., Fan, J., Ye, C., Dominguez, D., Zhang, Y., Curiel, T. J., Fang, D., Kuzel, T. M., & Zhang, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2331 · Cited by 103
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Miller, L. D., Chou, J., Black, M. A., Print, C. G., Chifman, J., Alistar, A. T., Putti, T. C., Zhou, X., Bedognetti, D., Hendrickx, W., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0149 · Cited by 101
Shou, D., Wen, L., Song, Z., Yin, J., Sun, Q., & Gong, W. (2016) · Oncotarget · doi:10.18632/oncotarget.11352 · Cited by 101
de Goeje, P. L., Bezemer, K., Heuvers, M. E., Dingemans, A. C., Groen, H. J. M., Smit, E. F., Hoogsteden, H. C., Hendriks, R. W., Aerts, J. G. J. V., & Hegmans, J. P. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1014242 · Cited by 100
The role of the interferon regulatory factor (IRF) family in dendritic cell development and function
Gabriele, L., & Ozato, K. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.008 · Cited by 98
The immunobiology of myeloid-derived suppressor cells in cancer
Motallebnezhad, M., Jadidi‐Niaragh, F., Qamsari, E. S., Bagheri, S., Gharibi, T., & Yousefi, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4477-9 · Cited by 97
Hassel, J. C., Jiang, H., Bender, C., Winkler, J. K., Sevko, A., Shevchenko, I., Halama, N., Dimitrakopoulou‐Strauss, A., Haefeli, W. E., Jäger, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1326440 · Cited by 97
Clavijo, P. E., Moore, E. C., Chen, J., Davis, R. J., Friedman, J., Kim, Y., Waes, C. V., Chen, Z., & Allen, C. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18437 · Cited by 97
Corn, P. G. (2012) · Cancer Management and Research · doi:10.2147/cmar.s32839 · Cited by 96
Nuhn, P., Vaghasia, A. M., Goyal, J., Zhou, X. C., Carducci, M. A., Eisenberger, M. A., & Antonarakis, E. S. (2013) · British Journal of Urology · doi:10.1111/bju.12531 · Cited by 96
CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1988-9 · Cited by 96
Cited by
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 460
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 290
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Metadata
- Authors
- De Cicco, P., Ercolano, G., & Ianaro, A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-30
- Volume
- 11
- Pages
- 1680-1680
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3046152640
- Cited by
- 332
- References
- 265
- FWCI
- 14.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.